Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors

Marker Therapeutics, Inc.

CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.
Non-employee directors David Eansor, Katherine Knobil, Steven Elms each receive 30,000 options.
Amendment corrects prior filing: grant date changed from Feb 12, 2024 to Feb 12, 2025.
All options are under the 2020 Omnibus Stock Ownership Plan and standard award agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.